// App-Quantinova.ai

: GUSELKUMAB WAS MORE EFFECTIVE THAN SECUKINUMAB IN PATIENTS WITH PLAQUE PSORIASIS AND THE SUBSET OF PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS IN THE RANDOMIZED, DOUBLE-BLIND, HEAD-TO-HEAD COMPARISON STUDY ECLIPSE OVER 1 YEAR

Researchers

Presenter

  • Joseph F. Merola

Principal Investigators

  • LI Shu

  • Ming-Chun Hsu

  • Chetan Karyekar

  • Susan Flavin

  • Bruce Randazzo

  • Laura C. Coates

Medical Centers

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • Janssen Research & Development, Raritan, United States of America

  • Janssen Medical Affairs, Horsham, United States of America

  • Oxford University, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Active Comparator

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved